Sanctuary Advisors LLC Sells 140 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Sanctuary Advisors LLC decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,077 shares of the biotechnology company’s stock after selling 140 shares during the quarter. Sanctuary Advisors LLC’s holdings in United Therapeutics were worth $3,902,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. World Investment Advisors LLC acquired a new position in shares of United Therapeutics during the third quarter valued at about $139,206,000. FMR LLC increased its stake in United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after acquiring an additional 314,004 shares during the period. AustralianSuper Pty Ltd raised its holdings in United Therapeutics by 577.1% in the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after acquiring an additional 161,751 shares in the last quarter. Assetmark Inc. lifted its position in shares of United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after acquiring an additional 152,249 shares during the period. Finally, Franklin Resources Inc. grew its holdings in shares of United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on UTHR shares. The Goldman Sachs Group raised their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. LADENBURG THALM/SH SH raised their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Oppenheimer upped their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $382.08.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This represents a 17.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, November 25th. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $960,576.75. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 124,164 shares of company stock worth $45,398,793. Insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $361.10 on Friday. The stock’s 50 day simple moving average is $362.68 and its 200 day simple moving average is $360.19. United Therapeutics Co. has a one year low of $214.75 and a one year high of $417.82. The firm has a market cap of $16.12 billion, a PE ratio of 15.86, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.